Cipla - Company Intelligence Profile
Industry: Pharmaceutical Manufacturing | Founded: 1935 | HQ: Mumbai, India
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years.
Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for Cipla to help teams evaluate the account with useful business context.
Company Snapshot
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years.
Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms.
Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients.
Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement.
An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.
Founded
Employee count
Monthly website visits
Open roles
Company Snapshot Details
Business signals that help qualify Cipla
This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.
Last refreshed 2026-05-03 | 110K search volume | Domain cipla.com
Cipla identity, aliases, ownership, and taxonomy
This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.
Cipla is a leading global pharmaceutical company that ensures access to quality and affordable medicines through 1500+ products across various therapeutic categories.
Built on the foundation of caring for life, Cipla ensures access to quality & affordable medicines through 1500+ products across various therapeutic categories.
LinkedIn followers
2.2M
Latest linkedin followers value available from the source dataset.
Owler followers
921
Latest owler followers value available from the source dataset.
Technologies detected
255
Latest technologies detected value available from the source dataset.
Operating status
Active
Independent Company
Company type
Public Company
type
Ownership status
Public
Ownership Status
Public company
Yes
Is Public
Company alias
cipla
Company Name Alias
Company alias
cipla inc
Company Name Alias
Company alias
cipla inc.
Company Name Alias
Website alias
https://www.cipla.com
Website Alias
Website alias
https://www.cipla.com/
Website Alias
Canonical website
https://www.cipla.com
website
Website domain
cipla.com
Website Domain
Unique website
Yes
Unique Website
Unique domain
Yes
Unique Domain
Expired domain
No
Expired Domain
LinkedIn shorthand
cipla
Canonical LinkedIn Shorthand Name
Source ID
37173
Source ID
UUID
0EJW8E6F88QC5C5HS2HXCHER0Z
uuid
SIC code
28
SIC Codes
SIC code
283
SIC Codes
NAICS code
32
NAICS Codes
NAICS code
325
NAICS Codes
Industry
Pharmaceutical Manufacturing
industry
Categories and keywords
['pharmaceutical', 'pharmaceuticals and active pharmaceutical ingredients', 'medicines', 'therapeutic categories', 'affordable', 'access', 'health', 'biotech', 'drug-development', 'pharma', 'biotechnology', 'health care', 'manufacturing', 'medical']
Categories And Keywords
LinkedIn followers
2.2M
Followers Count LinkedIn
Owler followers
921
Followers Count Owler
Primary location
Lower Parel; Ganpatrao Kadam Marg,; Mumbai, Maharashtra 400013, IN
Office location
Mispel St; Bellville, Western Cape 7530, ZA
Office location
Mumbai Central; Mumbai, Maharashtra 400008, IN
Office location
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel; mumbai, Maharashtra, India
Office location
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg,; Mumbai, 400013, India
Office location
Cipla House Peninsula Business Park Ganpatrao Kadam Marg; Mumbai, Maharashtra 400013, India
Office location
Mumbai, Maharashtra, India
Cipla revenue, funding, IPO, and acquisition history
Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.
Source 5
$3.3B
Annual revenue
IPO date
1995-02-08
IPO Date
Operating status
Active
Independent Company
Company type
Public Company
type
Ownership status
Public
Ownership Status
Public company
Yes
Is Public
Q3, 2026
Q3
Primary value
Revenue: INR 69.6B
Additional metrics
Gross profit: INR 46.5B; EBITDA: INR 14.6B; EBIT: INR 9.1B; Net income: INR 6.7B; Operating expense: INR 31.9B; Gross margin: 66.8%; EBITDA margin: 21.0%
Q2, 2026
Q2
Primary value
Revenue: INR 74.5B
Additional metrics
Gross profit: INR 53.6B; EBITDA: INR 21.6B; EBIT: INR 18.7B; Net income: INR 13.5B; Operating expense: INR 32B; Gross margin: 72.0%; EBITDA margin: 29.1%
Q1, 2026
Q1
Primary value
Revenue: INR 68.4B
Additional metrics
Gross profit: INR 50.5B; EBITDA: INR 20.4B; EBIT: INR 17.8B; Net income: INR 12.9B; Operating expense: INR 30.1B; Gross margin: 73.8%; EBITDA margin: 29.8%
FY, 2025
Fiscal Year
Primary value
Revenue: INR 271.5B
Additional metrics
Gross profit: INR 184.5B; EBITDA: INR 71.4B; EBIT: INR 62.3B; Net income: INR 52.9B; Operating expense: INR 113.2B; Gross margin: 68.0%; EBITDA margin: 26.3%
Q3, 2025
Q3
Primary value
Revenue: INR 69.6B
Additional metrics
Gross profit: INR 50.3B; EBITDA: INR 22.1B; EBIT: INR 19.3B; Net income: INR 15.8B; Operating expense: INR 28.2B; Gross margin: 72.3%; EBITDA margin: 31.8%
Q2, 2025
Q2
Primary value
Revenue: INR 69.6B
Additional metrics
Gross profit: INR 49.6B; EBITDA: INR 20.8B; EBIT: INR 18B; Net income: INR 13.1B; Operating expense: INR 28.8B; Gross margin: 71.2%; EBITDA margin: 29.8%
Q1, 2025
Q1
Primary value
Revenue: INR 66.2B
Additional metrics
Gross profit: INR 46.6B; EBITDA: INR 18.8B; EBIT: INR 16.3B; Net income: INR 11.8B; Operating expense: INR 27.9B; Gross margin: 70.4%; EBITDA margin: 28.3%
FY, 2024
Fiscal Year
Primary value
Revenue: INR 254.5B
Additional metrics
Gross profit: INR 168.2B; EBITDA: INR 63.2B; EBIT: INR 52B; Net income: INR 41.6B; Operating expense: INR 105.1B; Gross margin: 66.1%; EBITDA margin: 24.8%
Q3, 2024
Q3
Primary value
Revenue: INR 65.1B
Additional metrics
Gross profit: INR 45.7B; EBITDA: INR 19.3B; EBIT: INR 15B; Net income: INR 10.7B; Operating expense: INR 26.4B; Gross margin: 70.2%; EBITDA margin: 29.7%
Q2, 2024
Q2
Primary value
Revenue: INR 65.9B
Additional metrics
Gross profit: INR 45.4B; EBITDA: INR 19.1B; EBIT: INR 16.2B; Net income: INR 11.6B; Operating expense: INR 26.3B; Gross margin: 68.9%; EBITDA margin: 29.0%
Q1, 2024
Q1
Primary value
Revenue: INR 62.7B
Additional metrics
Gross profit: INR 42.3B; EBITDA: INR 16.3B; EBIT: INR 13.9B; Net income: INR 10B; Operating expense: INR 26B; Gross margin: 67.4%; EBITDA margin: 26.0%
FY, 2023
Fiscal Year
Primary value
Revenue: INR 224.7B
Additional metrics
Gross profit: INR 193.4B; EBITDA: INR 99.8B; EBIT: INR 87.1B; Net income: INR 78B; Operating expense: INR 93.8B; Gross margin: 86.0%; EBITDA margin: 44.4%
| Period | Primary value | Additional metrics |
|---|---|---|
Q3, 2026 Q3 | Revenue: INR 69.6B | Gross profit: INR 46.5B; EBITDA: INR 14.6B; EBIT: INR 9.1B; Net income: INR 6.7B; Operating expense: INR 31.9B; Gross margin: 66.8%; EBITDA margin: 21.0% |
Q2, 2026 Q2 | Revenue: INR 74.5B | Gross profit: INR 53.6B; EBITDA: INR 21.6B; EBIT: INR 18.7B; Net income: INR 13.5B; Operating expense: INR 32B; Gross margin: 72.0%; EBITDA margin: 29.1% |
Q1, 2026 Q1 | Revenue: INR 68.4B | Gross profit: INR 50.5B; EBITDA: INR 20.4B; EBIT: INR 17.8B; Net income: INR 12.9B; Operating expense: INR 30.1B; Gross margin: 73.8%; EBITDA margin: 29.8% |
FY, 2025 Fiscal Year | Revenue: INR 271.5B | Gross profit: INR 184.5B; EBITDA: INR 71.4B; EBIT: INR 62.3B; Net income: INR 52.9B; Operating expense: INR 113.2B; Gross margin: 68.0%; EBITDA margin: 26.3% |
Q3, 2025 Q3 | Revenue: INR 69.6B | Gross profit: INR 50.3B; EBITDA: INR 22.1B; EBIT: INR 19.3B; Net income: INR 15.8B; Operating expense: INR 28.2B; Gross margin: 72.3%; EBITDA margin: 31.8% |
Q2, 2025 Q2 | Revenue: INR 69.6B | Gross profit: INR 49.6B; EBITDA: INR 20.8B; EBIT: INR 18B; Net income: INR 13.1B; Operating expense: INR 28.8B; Gross margin: 71.2%; EBITDA margin: 29.8% |
Q1, 2025 Q1 | Revenue: INR 66.2B | Gross profit: INR 46.6B; EBITDA: INR 18.8B; EBIT: INR 16.3B; Net income: INR 11.8B; Operating expense: INR 27.9B; Gross margin: 70.4%; EBITDA margin: 28.3% |
FY, 2024 Fiscal Year | Revenue: INR 254.5B | Gross profit: INR 168.2B; EBITDA: INR 63.2B; EBIT: INR 52B; Net income: INR 41.6B; Operating expense: INR 105.1B; Gross margin: 66.1%; EBITDA margin: 24.8% |
Q3, 2024 Q3 | Revenue: INR 65.1B | Gross profit: INR 45.7B; EBITDA: INR 19.3B; EBIT: INR 15B; Net income: INR 10.7B; Operating expense: INR 26.4B; Gross margin: 70.2%; EBITDA margin: 29.7% |
Q2, 2024 Q2 | Revenue: INR 65.9B | Gross profit: INR 45.4B; EBITDA: INR 19.1B; EBIT: INR 16.2B; Net income: INR 11.6B; Operating expense: INR 26.3B; Gross margin: 68.9%; EBITDA margin: 29.0% |
Q1, 2024 Q1 | Revenue: INR 62.7B | Gross profit: INR 42.3B; EBITDA: INR 16.3B; EBIT: INR 13.9B; Net income: INR 10B; Operating expense: INR 26B; Gross margin: 67.4%; EBITDA margin: 26.0% |
FY, 2023 Fiscal Year | Revenue: INR 224.7B | Gross profit: INR 193.4B; EBITDA: INR 99.8B; EBIT: INR 87.1B; Net income: INR 78B; Operating expense: INR 93.8B; Gross margin: 86.0%; EBITDA margin: 44.4% |
Post-IPO Secondary
Life Insurance Corporation
Inzpera Healthsciences
$12.4M
2025-11-01 | Acquisition List Source 5
Ivia Beaute Pvt Ltd's Cosmetics and Personal Care Distribution and Marketing Business
$15.6M
2024-04-01 | Acquisition List Source 5
Actor
INR 3.9B
2024-02-07 | Acquisition List Source 1
Productiv, Wanbury Ltd
Acquisition
2020-02-01 | Acquisition List Source 5
CPink, Wanbury Ltd
Acquisition
2020-02-01 | Acquisition List Source 5
Folinine, Wanbury Ltd
Acquisition
2020-02-01 | Acquisition List Source 5
CDense, Wanbury Ltd
Acquisition
2020-02-01 | Acquisition List Source 5
Mirren
INR 2.2B
2018-10-22 | Acquisition List Source 1
Cipla Medpro South Africa Ltd.
$33M
2018-07-12 | Acquisition List Source 2
InvaGen
Acquisition
2016-02-17 | Acquisition List Source 1
Exelan Pharmaceuticals
Acquisition
2016-02-17 | Acquisition List Source 1
Exelan Pharmaceuticals
$50M
2015-09-04 | Acquisition List Source 2
InvaGen Pharmaceuticals
$500M
2015-09-04 | Acquisition List Source 2
Quality Chemicals
INR 1.9B
2015-08-06 | Acquisition List Source 1
Quality Chemicals Ltd
$30M
2015-05-25 | Acquisition List Source 2
Jay Precision Pharmaceuticals
INR 960M
2015-02-26 | Acquisition List Source 1
Saba Investment
$21M
2014-10-02 | Acquisition List Source 1
Celeris
Acquisition
2013-12-04 | Acquisition List Source 1
Cipla Cipla Medpro
INR 27.6B
2013-07-15 | Acquisition List Source 1
Meditab Specialities
$24.8M
2011-11-23 | Acquisition List Source 2
Meditab Specialities
INR 1.3B
2010-10-01 | Acquisition List Source 1
Goldencross Pharma
INR 1.9B
2010-05-14 | Acquisition List Source 1
Cipla Select (Pty) Limited
Acquisition
Acquisition List Source 1
Meditab Specialities Limited
Acquisition
Acquisition List Source 1
Cipla Dibcare (Pty) Limited
Acquisition
Acquisition List Source 1
Cipla Maroc SA
Acquisition
Acquisition List Source 1
Mexicip S.A. de C.V.
Acquisition
Acquisition List Source 1
Cipla Medpro Manufacturing (Pty) Limited
Acquisition
Acquisition List Source 1
Cipla Philippines Inc.
Acquisition
Acquisition List Source 1
Cipla Gulf FZ-LLC
Acquisition
Acquisition List Source 1
Cipla Australia Pty Limited
Acquisition
Acquisition List Source 1
Cipla Colombia SAS
Acquisition
Acquisition List Source 1
Cipla Kenya Limited
Acquisition
Acquisition List Source 1
Meditab Holdings Limited
Acquisition
Acquisition List Source 1
Cipla Medpro South Africa (Pty) Limited
Acquisition
Acquisition List Source 1
Mirren (Pty) Ltd.
Acquisition
Acquisition List Source 1
The Cipla Empowerment Trust
Acquisition
Acquisition List Source 1
Cipla (Jiangsu) Pharmaceutical Co., Ltd.
Acquisition
Acquisition List Source 1
Medispray Laboratories Private Limited
Acquisition
Acquisition List Source 1
Jay Precision Pharmaceuticals Private Limited
Acquisition
Acquisition List Source 1
Goldencross Pharma Limited
Acquisition
Acquisition List Source 1
Cipla-Medpro Distribution Centre (Pty) Limited
Acquisition
Acquisition List Source 1
Cipla Health Limited
Acquisition
Acquisition List Source 1
Cipla Digital Health Limited
Acquisition
Acquisition List Source 1
Cipla Brasil Importadora E Distribuidora de Medicamentos Ltda.
Acquisition
Acquisition List Source 1
Cipla (China) Pharmaceutical Co., Ltd.
Acquisition
Acquisition List Source 1
Cipla Health Employee Stock Option Trust
Acquisition
Acquisition List Source 1
Medpro Pharmaceutica (Pty) Limited
Acquisition
Acquisition List Source 1
Exelan Pharmaceuticals Inc.
Acquisition
Acquisition List Source 1
Cipla-Medpro (Pty) Limited
Acquisition
Acquisition List Source 1
Aspergen Inc.
Acquisition
Acquisition List Source 1
Sitec Labs Limited
Acquisition
Acquisition List Source 1
InvaGen Pharmaceuticals Inc.
Acquisition
Acquisition List Source 1
Cipla Medpro Botswana (Pty) Limited
Acquisition
Acquisition List Source 1
Cipla (EU) Limited
Acquisition
Acquisition List Source 1
Cipla USA Inc.
Acquisition
Acquisition List Source 1
Breathe Free Lanka (Private) Limited
Acquisition
Acquisition List Source 1
Cipla Therapeutics Inc.
Acquisition
Acquisition List Source 1
Cipla Pharmaceuticals Limited
Acquisition
Acquisition List Source 1
Actor Pharma (Pty) Limited
Acquisition
Acquisition List Source 1
Cipla Europe NV
Acquisition
Acquisition List Source 1
Cipla Pharma and Life Sciences Limited
Acquisition
Acquisition List Source 1
Cipla Holding B.V.
Acquisition
Acquisition List Source 1
Cipla Malaysia Sdn. Bhd.
Acquisition
Acquisition List Source 1
Inzpera Store
Acquisition
Acquisition List Source 2
Web visibility, demand, and topics
Use these signals to understand discoverability, demand quality, search interest, and audience fit.
Monthly visits
204.7K
Latest monthly visits value available from the source dataset.
Global web rank
#197,162
Lower rank values indicate stronger web visibility in the source dataset.
Bounce rate
41.0%
Latest bounce rate value available from the source dataset.
Pages per visit
2.94
Latest pages per visit value available from the source dataset.
Average visit duration
1m 4s
Latest average visit duration value available from the source dataset.
Estimated monthly page views
601.7K
Derived estimate calculated as monthly visits multiplied by pages per visit.
cipla
Associated search topic
cipla ltd
Associated search topic
www.secondary.cipla.com
Associated search topic
cipla limited
Associated search topic
cipla financial report:pdf
Associated search topic
LinkedIn followers
2.2M
Followers Count LinkedIn
Owler followers
921
Followers Count Owler
Employees, hiring, attrition, and compensation
This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.
Employees
51.3K
Latest employees value available from the source dataset.
Inferred employees
16.3K
Latest inferred employees value available from the source dataset.
Open roles
15
Latest open roles value available from the source dataset.
Departures
0
Latest departures value available from the source dataset.
Employee attrition rate
0.0%
Latest employee attrition rate value available from the source dataset.
Hiring intensity
0.3 roles / 1K employees
Derived signal showing open roles normalized by employee count.
Key Account Manager – Ventas Institucionales
Open role
4403445976
Medical Sales Representative
Open role
4407157585
Country Manager - Russia
Open role
4399244207
Medical Sales Representative
Open role
4404598496
Key Account Manager - Pharmacy Corporation
Open role
4403819223
Medical Delegate
Open role
4386309870
Officer - EHS
Open role
4079421494
Key Account Manager - Pharmacy Corporation
Open role
4409432015
Showing 8 of 15 available records.
Showing 8 of 10 available records.
Showing 8 of 10 available records.
Key Account Manager
INR $950K
Annual | Updated 2024-09-12
CA Industrial Trainee
INR $175.5K
Annual | Updated 2024-03-08
Associate
INR $330.1K
Monthly | Updated 2024-08-24
Manufacturing Supervisor
USD $77.8K
Annual
Analytical Chemist
USD $67.3K
Annual
Business Manager
INR $599.4K
Annual | Updated 2024-09-21
Senior Product Manager
INR $817.5K
Monthly | Updated 2023-12-16
Data Scientist
INR $848.5K
Annual | Updated 2023-09-13
Showing 8 of 10 available records.
Production Supervisor
Cash Bonus $31.6K
Monthly | Updated 2024-08-06
Brand Manager
Cash Bonus $102.3K
Annual | Updated 2024-07-30
QC Chemist
Cash Bonus $3.2K
Annual
Pmt
Cash Bonus $44.5K
Annual | Updated 2023-01-05
Business Analyst
Cash Bonus $342.9K
Annual | Updated 2024-07-11
Production Executive
Cash Bonus $122.5K
Monthly | Updated 2021-06-10
Project Manager
Cash Bonus $5.9K
Annual
Scientist
Cash Bonus $4.7K
Annual
Showing 8 of 10 available records.
Business Manager
INR $599.4K
Annual | Updated 2024-09-21
Asst Manager
INR $725K
Annual | Updated 2024-09-13
Key Account Manager
INR $1.1M
Annual | Updated 2024-09-12
Regional Sales Manager
INR $1.2M
Annual | Updated 2024-09-10
Regional Manager
INR $1.4M
Annual | Updated 2024-09-10
Senior Executive
INR $312.7K
Annual | Updated 2024-09-06
Deputy Manager
INR $1.2M
Annual | Updated 2024-09-04
Executive
INR $318.5K
Annual | Updated 2024-09-04
Showing 8 of 10 available records.
Product readiness, customer proof, and employee sentiment
Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.
Employee reviews
1.8K
Latest employee reviews value available from the source dataset.
Employee rating
3.8
Latest review score available from the source dataset.
Is pricing information available?
No. The source snapshot does not list pricing information for this company.
Source availability signal
Is a free trial listed?
No. The source snapshot does not list a free trial for this company.
Source availability signal
Can buyers request a demo?
No. The source snapshot does not list a demo motion for this company.
Source availability signal
Is the product downloadable?
No. The source snapshot does not list downloadable software for this company.
Source availability signal
Are mobile apps listed?
No. The source snapshot does not list mobile apps for this company.
Source availability signal
Is public documentation listed?
No. The source snapshot does not list public documentation for this company.
Source availability signal
Are online reviews listed?
No. The source snapshot does not list online reviews for this company.
Source availability signal
Technology, leadership, competitors, funding, and corporate activity
These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.
Azure Data Factory
Verified technology
Last verified 2026-05-04 | First seen 2026-05-03
Verified technology
Last verified 2026-05-04 | First seen 2024-04-04
Seg
Verified technology
Last verified 2026-05-04 | First seen 2026-03-09
Microsoft Windows Xp
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Delphi
Verified technology
Last verified 2026-05-04 | First seen 2026-01-25
Packer
Verified technology
Last verified 2026-05-04 | First seen 2026-01-25
Ams
Verified technology
Last verified 2026-05-04 | First seen 2025-08-31
Servicenow
Verified technology
Last verified 2026-05-04 | First seen 2026-04-28
Showing 8 of 24 available records.
Showing 8 of 12 available records.
Sabari Girisan R
Human Resources Business Partner
Vaibhav Vaidya
Associate Director
Pankaj Mahajan
Executive
Lakhvir Singh
Executive
shikandar sawakhande
Electrical Head
Tushar Rajyaguru
Director
Subrata Kundu
Executive
AJITHKUMAR T S
Executive
Showing 8 of 12 available records.
Ashish Arora
Marketing Head
Dec 2025
Aditi Garg
Head - Strategy, M&A, Digital Transformation, One India Business
Feb 2026
Pankaj Kumar Thakur
Director
Apr 2026
Riyazkhan Mulani
Associate Director
Feb 2026
Paras Patidar
Executive
Dec 2025
Nandan Singh
Lead - Talent Acquisition (One India Business)
Feb 2026
Atish Desai
Unit head
Apr 2026
Jeet Biswas
Self Employed
Jan 2026
Sahil KHAN
Executive
Mar 2026
Joy Dsouza
Country Head - Cipla Germany
Jan 2026
Ashish Zitshi
Site Head
Feb 2026
Anjali Sharma
Human Resources Business Partner
Mar 2026
Aniket Jadhav
Executive
Dec 2025
Ajay Thakur
Executive
Mar 2026
Aditi Garg
Head - Corporate Strategy
Jan 2026
Aditya Mall
Group Brand Lead
Dec 2025
Primary location
Lower Parel; Ganpatrao Kadam Marg,; Mumbai, Maharashtra 400013, IN
Office location
Mispel St; Bellville, Western Cape 7530, ZA
Office location
Mumbai Central; Mumbai, Maharashtra 400008, IN
Office location
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel; mumbai, Maharashtra, India
Office location
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg,; Mumbai, 400013, India
Office location
Cipla House Peninsula Business Park Ganpatrao Kadam Marg; Mumbai, Maharashtra 400013, India
Office location
Mumbai, Maharashtra, India
Cipla Emerging Markets and Europe (EMEU) team has been recognised at the Viksit Bharat AI Honours 2026, organ…
79 reactions; 7 comments
2026-04-30 | Cipla Emerging Markets and Europe (EMEU) team has been recognised at the Viksit Bharat AI Honours 2026, organised by the Regenesys School of AI.
We’re here! Our Cipla USA team is proud to be at Asembia Summit 2026 in Las Vegas, one of our favorite annual…
104 reactions; 3 comments
2026-04-27 | We’re here! Our Cipla USA team is proud to be at Asembia Summit 2026 in Las Vegas, one of our favorite annual gatherings to connect, collaborate, and build lasting partnerships. We look forward to seeing familiar faces…
It’s a hat-trick for Cipla at the AmbitionBox Employee Choice Awards (ABECA), with recognition for the third…
181 reactions; 8 comments
2026-04-24 | It’s a hat-trick for Cipla at the AmbitionBox Employee Choice Awards (ABECA), with recognition for the third consecutive year! Top Rated Large Company – 2nd year in a row Top Rated Pharma Company – 3rd year in a row #C…
Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA. Click here to read more: https…
328 reactions; 20 comments
2026-04-23 | Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA. Click here to read more: https://lnkd.in/dDGJ5jJX
Cipla's Pink of Health campaign recognised with two awards at the e4m Impact Digital Influencer Awards in the…
60 reactions; 1 comments
2026-04-23 | Cipla's Pink of Health campaign recognised with two awards at the e4m Impact Digital Influencer Awards in the Category: Health, Wellness and Fitness.
Rooted in a rich legacy and guided by our purpose of #CaringForLife, we are driven to build a healthier futur…
62 reactions; 1 comments
2026-04-21 | Rooted in a rich legacy and guided by our purpose of #CaringForLife, we are driven to build a healthier future by advancing patient-centric innovations harnessing digital technologies, to make a tangible difference for…
SIC code
28
SIC Codes
SIC code
283
SIC Codes
NAICS code
32
NAICS Codes
NAICS code
325
NAICS Codes
Industry
Pharmaceutical Manufacturing
industry
Categories and keywords
['pharmaceutical', 'pharmaceuticals and active pharmaceutical ingredients', 'medicines', 'therapeutic categories', 'affordable', 'access', 'health', 'biotech', 'drug-development', 'pharma', 'biotechnology', 'health care', 'manufacturing', 'medical']
Categories And Keywords
Cipla FAQs
Company profile
Want verified contact data for Cipla?
Datakart.ai gives you verified email addresses, direct dials, and buying intent signals for key decision-makers at Cipla and 1,700+ other companies.